Tetracyclines and Chloramphenicol

Tetracyclines — Classification

Short: tetracycline, oxytetracycline, chlortetracycline. Intermediate: demeclocycline. Long: doxycycline, minocycline. Glycylcycline(engineered vs classic resistance): tigecycline.

Tetracyclines — Mechanism

Reversibly bind 30S ribosome, block A-site(aminoacyl site) → no incoming aminoacyl-tRNA → protein synthesis stalls. REVERSIBLE(vs aminoglycoside’s near-irreversible 30S binding) → BACTERIOSTATIC(consistent with General Considerations pattern).

Tetracyclines — Adverse Effects

Bone/teeth deposition: chelates Ca2+ in actively mineralizing tissue → permanent tooth discolouration(yellow-grey-brown, worse if during primary tooth development) + impaired bone growth in children → CI children <8 + pregnancy(crosses placenta) — mechanism-driven, not arbitrary cutoff. Phototoxicity(class-wide, esp demeclocycline). Vestibular toxicity(dizziness/ataxia) = distinctive MINOCYCLINE effect. Hepatotoxicity(high-dose IV, esp pregnancy — acute fatty liver of pregnancy risk, historically significant). Chelation with divalent/trivalent cations(SAME mechanism as fluoroquinolones — antacids, dairy, iron) → ↓absorption, manage by timing separation.

Tetracyclines — Uses

Broad incl. ATYPICALS(Rickettsia, Chlamydia, Mycoplasma — no cell wall/intracellular, β-lactams can’t reach) → 1st-line atypical pneumonia, RMSF, Lyme disease. Doxycycline: malaria prophylaxis + acne(low-dose, anti-inflammatory not just antibacterial). Demeclocycline: SEPARATE non-antibacterial use — antagonizes ADH at collecting duct → induces nephrogenic DI → used for SIADH(corrects hyponatraemia by blunting kidney’s ADH response) — “opposite of usual purpose,” high-yield.

Chloramphenicol — Mechanism

Binds 50S ribosome, inhibits peptidyl transferase(blocks peptide bond formation) — distinct from tetracycline’s A-site block, other subunit. BACTERIOSTATIC most organisms, BACTERICIDAL vs H. influenzae/N. meningitidis/S. pneumoniae(exception, not uniform).

Chloramphenicol — Adverse Effects

Aplastic anaemia = defining SE, TWO DISTINCT mechanisms: (1) Dose-related, REVERSIBLE bone marrow suppression — mitochondrial protein synthesis inhibition(mitochondrial ribosomes structurally bacteria-like, evolutionary origin) — predictable, resolves on dose↓/stop. (2) Idiosyncratic, NON-dose-related, IRREVERSIBLE aplastic anaemia — genetically predisposed, unpredictable, NOT prevented by dose adjustment → THIS form = actual reason for restricted use today(no monitoring prevents it) despite good spectrum/low cost.

Grey baby syndrome: neonates(esp premature) have IMMATURE hepatic glucuronyl transferase(chloramphenicol depends on this for conjugation/inactivation) → unconjugated drug accumulates → cardiovascular collapse, cyanosis(“grey”), abdominal distension. Distinct mechanism from both aplastic anaemia pathways.

Chloramphenicol — Interactions & Uses

Potent CYP450 INHIBITOR → ↑levels of co-drugs — classic examples: phenytoin, warfarin(both narrow-TI, meaningful ↑toxicity risk).

Uses restricted by toxicity to where advantages(CNS penetration, broad spectrum incl anaerobes, low cost) outweigh risk + no adequate alternative: bacterial meningitis(resource-limited settings/penicillin-allergic), rickettsial infections, TOPICAL use(eye drops — minimal systemic absorption/toxicity risk) remains common+appropriate.

Clinical Relevance

Both drugs = same lesson, different angle: selective toxicity is NEVER absolute — understanding WHY an off-target effect occurs(chloramphenicol’s mitochondrial ribosome cross-reactivity; tetracycline’s Ca2+-chelation in mineralizing tissue) correctly PREDICTS which patients are at risk(neonates for grey baby via immature glucuronidation; children/pregnant for tetracycline bone/tooth effects) — not an arbitrary age/population cutoff to memorize independent of mechanism.

Tetracyclines

Classification

Short-acting: tetracycline, oxytetracycline, chlortetracycline
Intermediate-acting: demeclocycline
Long-acting: doxycycline, minocycline
Glycylcycline (structurally related, engineered to overcome classic tetracycline resistance mechanisms): tigecycline

Mechanism of Action

Tetracyclines reversibly bind the bacterial 30S ribosomal subunit, specifically blocking the A-site (aminoacyl site) and preventing incoming aminoacyl-tRNA from binding there — without a new amino acid able to attach to the growing peptide chain, protein synthesis stalls. This is a reversible interaction (unlike aminoglycosides’ effectively irreversible 30S binding), consistent with tetracyclines being bacteriostatic rather than bactericidal, per the general pattern established under Antimicrobials — General Considerations.

Adverse Effects

Deposition in developing bone and teeth — tetracyclines chelate calcium, and this chelation in actively mineralizing tissue causes permanent tooth discolouration (yellow-grey-brown staining, more marked with primary/deciduous teeth if exposure occurs during tooth development) and can impair bone growth in children — the specific, mechanism-driven reason tetracyclines are contraindicated in children under 8 and in pregnancy (crosses the placenta, affecting fetal tooth/bone development), a genuinely high-yield contraindication tied directly to the chelation mechanism rather than an arbitrary age cutoff. Phototoxicity (exaggerated sunburn reaction) is class-wide but particularly notable with demeclocycline. Vestibular toxicity (dizziness, ataxia) is a distinctive, comparatively more prominent adverse effect of minocycline specifically among the tetracyclines. Hepatotoxicity with high-dose IV use, particularly in pregnancy (a specific, historically-significant risk — acute fatty liver of pregnancy associated with high-dose IV tetracycline, now largely avoided by not using this route/dose in pregnant patients). Chelation with divalent/trivalent cations (the same interaction mechanism as fluoroquinolones under Quinolones — antacids, dairy, iron) substantially reduces oral absorption, managed by timing separation.

Uses

Broad-spectrum coverage including many atypical organisms — Rickettsia, Chlamydia, Mycoplasma (organisms lacking a cell wall or with intracellular life cycles that β-lactams cannot address) — making tetracyclines/doxycycline first-line for atypical pneumonia, Rocky Mountain spotted fever, and Lyme disease. Doxycycline is also used for malaria prophylaxis and, notably, for acne (a lower-dose, longer-course use exploiting its anti-inflammatory rather than purely antibacterial property against Cutibacterium acnes). Demeclocycline has a distinctive, separate, non-antibacterial use: inducing nephrogenic diabetes insipidus by antagonizing ADH action at the renal collecting duct — used therapeutically for SIADH (syndrome of inappropriate ADH), deliberately blunting the kidney’s response to excess ADH to correct the resulting hyponatraemia, a specific, frequently examined “opposite of the drug’s usual purpose” fact.

Chloramphenicol

Mechanism of Action

Binds the 50S ribosomal subunit, inhibiting peptidyl transferase — the enzyme responsible for forming the peptide bond between the growing polypeptide chain and the newly-arrived amino acid — blocking peptide bond formation directly, distinct from tetracycline’s A-site-blocking mechanism at the other ribosomal subunit. Bacteriostatic against most organisms, though bactericidal against a few specific ones (Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae) — an exception worth flagging rather than assuming uniform bacteriostatic activity.

Adverse Effects

Aplastic anaemia is chloramphenicol’s defining, most feared adverse effect, and it occurs by two mechanistically distinct pathways worth clearly separating: (1) a dose-related, reversible bone marrow suppression (mitochondrial protein synthesis inhibition — chloramphenicol’s ribosomal-binding mechanism has some off-target activity against mitochondrial ribosomes, which are structurally more bacteria-like than the cytoplasmic eukaryotic ribosome, reflecting mitochondria’s evolutionary bacterial origin), predictable and resolving on dose reduction/discontinuation; and (2) a rare, idiosyncratic, non-dose-related, and irreversible aplastic anaemia, genetically predisposed and not predictable or preventable by dose adjustment — this second, unpredictable form is the actual reason chloramphenicol use is so restricted today despite its excellent broad-spectrum activity and low cost, since no monitoring strategy reliably prevents it. Grey baby syndrome: neonates (particularly premature infants) have immature hepatic glucuronyl transferase, the enzyme chloramphenicol normally depends on for conjugation/inactivation — accumulating unconjugated drug causes cardiovascular collapse, cyanosis (the “grey” colour), and abdominal distension, a specific, mechanistically clear, developmentally-timed toxicity distinct from either aplastic anaemia mechanism above.

Drug Interactions

Chloramphenicol is a potent CYP450 inhibitor, raising levels of numerous co-administered drugs — phenytoin and warfarin are the classic, specifically examined examples, both narrow-therapeutic-index drugs where chloramphenicol co-administration meaningfully raises toxicity risk.

Uses

Given its toxicity profile, chloramphenicol’s use today is largely restricted to situations where its specific advantages (excellent CNS penetration, broad spectrum including anaerobes, low cost) outweigh the risk and no adequate alternative exists — bacterial meningitis in resource-limited settings or specific penicillin-allergic scenarios, rickettsial infections, and topical use (eye drops, where systemic absorption and therefore systemic toxicity risk is minimal) remains common and appropriate.

Clinical Relevance

Both drugs in this topic illustrate the same broader lesson from a different angle: a drug’s mechanism of selective toxicity is never absolute, and understanding why an off-target effect occurs (chloramphenicol’s mitochondrial ribosome cross-reactivity, tetracycline’s calcium-chelation in mineralizing tissue) is what correctly predicts which patients are at elevated risk (neonates for chloramphenicol’s grey baby syndrome via immature glucuronidation, children/pregnant patients for tetracycline’s bone/tooth effects) rather than treating the contraindication as an arbitrary age or population cutoff to memorize independent of mechanism.

30S (tetracycline, A-site block) vs 50S (chloramphenicol, peptidyl transferase block) ribosomal binding sites side by side.
Two distinct chloramphenicol aplastic anaemia pathways (dose-related reversible vs idiosyncratic irreversible) contrasted.
Grey baby syndrome mechanism: immature neonatal glucuronyl transferase and unconjugated drug accumulation.